Sarcoma botryoides surgery

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Sarcoma botryoides Microchapters
Home
Patient Information
Overview
Historical perspective
Classification
Pathophysiology
Causes
Differentiating Sarcoma botryoides from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural history, Complications, and Prognosis
Diagnosis
Staging
History and Symptoms
Physical Examination
Laboratpory Tests
Pelvic X Ray
MRI
CT
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Sarcoma botryoides surgery On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Sarcoma botryoides surgery All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Sarcoma botryoides surgery
CDC on Sarcoma botryoides surgery
Sarcoma botryoides surgery in the news
Blogs on Sarcoma botryoides surgery
Directions to Hospitals Treating Sarcoma botryoides
Risk calculators and risk factors for Sarcoma botryoides surgery

Overview

Sarcoma botryoides, also known as embryonal rhabdomyosarcoma, is a type of rhabdomyosarcoma in the vagina of young girls, typically younger than 8. The name comes from the gross appearance of "grape bunches" (botryoid in Greek).

Surgery

The disease used to be uniformly fatal, with a 5-year survival rate between 10 to 35% (Piver and Rose, 1988). As a result, treatment was radical surgery. New multidrug chemotherapy regimens with or without radiation therapy are now used in combination with less radical surgery with good results, although outcome data are not yet available (Rotmensch and Yamada, 2003).